WASHINGTON, D.C. — The U.S. Department of Health and Human Services announced investments up to $4.9 million through the Advanced Research Projects Agency for Health on Thursday to advance the development of ibogaine as a potential treatment for post-traumatic stress disorder and other serious mental illnesses. The agency’s initial commitment is up to $4.9 million over five years.
HHS Secretary Robert F. Kennedy, Jr., made the announcements alongside leaders from the Department of Veterans Affairs. "Veterans kept their promise to this country. We must keep ours," said Secretary Kennedy. "Veterans have told us ibogaine changed their lives. Their experiences demand serious scientific investigation. We will pursue the evidence, confront the risks and put affordability at the center of this work."
Research teams selected by ARPA-H are led by the Mark Cuban Cost Plus Drug Company, PBC, and Beond, Inc. The Mark Cuban Cost Plus Drug Company, PBC, will establish the regulatory, clinical, chemical, and engineering foundation for a domestically manufactured, single-molecule ibogaine hydrochloride product for potential PTSD treatment. Beond, Inc., will deliver high-fidelity clinical data to evaluate the safety, dosing, efficacy, and durability of ibogaine.
The ARPA-H efforts support preparation of Investigational New Drug Applications to enable future clinical trials in the United States, secure clinical-grade ibogaine, and develop processes for sustainable domestic manufacturing. The awards fund the regulatory and manufacturing groundwork for future trials. Performer awards vary in funding amount per awardee and are contingent upon each team meeting aggressive and accelerated research milestones.
The funding does not fund treatment of patients or human-subject research, and it does not authorize clinical trials or establish FDA approval. Ibogaine carries serious safety risks, including potentially life-threatening heart rhythm problems. If development succeeds and the medicine earns FDA approval, the goal is to make it available at the cost of production plus a fair margin.
All awardees will open-source data from their research findings. HHS committed to making research findings public, whether they show benefit, no benefit or harm, while protecting patient privacy. Additional awards are expected that will include a focus on ibogaine as a potential treatment for substance use disorders. Future ARPA-H awards will evaluate ibogaine as a potential treatment for substance use disorders, including opioid use disorder.
"We owe veterans more than promises," said Secretary Kennedy. "We owe them rigorous science, honest answers and a path to affordable care if the evidence supports it." VA Secretary Doug Collins said "veterans deserve effective treatments and clear answers about the benefits and risks of those treatments." "We look forward to working with HHS to explore the possibilities of ibogaine and prepare our clinicians to deliver new treatments if they earn FDA approval," Collins said.
The National Institute of Mental Health published a $20 million Notice of Funding Opportunity to support the development of a research network to study rapid-acting psychotropic interventional drugs such as ketamine, esketamine, and psilocybin. Award recipients for the National Institute of Mental Health funding opportunity will be announced in the summer of 2027. The announcement advances President Trump’s April directive to accelerate research into promising psychedelic treatments.
Why It Matters
In 2023, two observational studies on ibogaine treatment for PTSD in Special Operations Forces (SOF) Veterans showed reductions in PTSD symptoms and suicidal ideation, with effects lasting up to 6 months post-treatment. Al Bugazia, M.D., Senior Advisor for Special Projects at ARPA-H, said reports of successful ibogaine treatments are too promising to ignore. Primary source: ptsd.va.gov
forum Comments (0)
No comments yet. Be the first to comment.